DNA topoisomerase II is an essential nuclear enzyme that relaxes supercoiled DNA in an ATP-dependent manner by transiently introducing double-stranded breaks (for reviews see Wang, 1985; Watt and Hickson, 1994) . Several of the most effective drugs used to treat small-cell lung cancer and leukaemia cause topoisomerase 11-mediated DNA damage and subsequent cell death (Liu, 1989) . Repetitive treatment with these chemotherapeutic agents often leads to multidrug resistance (MDR) in the targeted cells and failure of the chemotherapy. MDR can be acquired either through an increase in the level of P-glycoprotein, a plasma membrane efflux pump (reviewed in Endicott and Ling, 1989) , or through alterations in DNA topoisomerase II levels, its primary structure and/or its phosphorylation state (reviewed in Beck et al., 1993; Pommier, 1993; Corbett and Osheroff, 1993; Vassetzky et al., 1995) . In many drug-resistant mammalian cell lines, alterations in both P-glycoprotein and DNA topoisomerase II are found (e.g. Granzen et al., 1992) , making it difficult to characterise and counteract drug resistance.
DNA topoisomerases are the targets of a large variety of commonly used anti-cancer drugs, which generally fall into two classes: those that intercalate DNA, such as amsacrines, and those that do not, such as epipodophyllotoxins (Liu, 1989) . Although the literature on DNA topoisomerase II inhibition is extensive, in most cases it is still unclear how the drugs interact with topoisomerase II. Recently, a large number of DNA topoisomerase II mutations conferring drug resistance have been identified in cells of different origins, including yeast (Jannatipour et al., 1993; Wasserman et al., 1993; Wasserman and Wang, 1994a, b) , cultured mammalian cells and primary explants of tumours (Bugg et al., 1991; Chan et al., 1993; Hinds et al., 1991; Lee et al., 1992; Campain et al., 1994; Feldhoff et al., 1994 ) that spontaneously developed drug resistance. The mutations within the topoisomerase II gene that confer drug resistance can be classified into three groups: (1) mutations clustered between aa 449 and aa 493, which appear to affect the ATPbinding domain; (2) mutations close to the active site (located at aa 783 in yeast, aa 804 in human); and (3) mutations that modulate the phosphorylation of the C-terminal domain of topoisomerase II or which truncate the enzyme (Wasserman and Wang, 1994a, b; McPherson et al., 1993; Takano et al., 1991) . The first two groups are characterised by a reduced DNA cleavage activity (e.g. Lee et al., 1992; Liu et al., 1991) , which may explain the resistance phenotype, since less DNA damage might be provoked by less active enzymes. The third group is more enigmatic, since it was shown that the Cterminal 220 aa of DNA topoisomerase II is not essential for the enzymatic activity of the enzyme in Schizosaccharomyces pombe (Shiozaki and Yanagida, 1991) , Drosophila melanogaster or Saccharomyces cerevisiae (Caron et al., 1994; Crenshaw and Hsieh, 1993a,b) , although it contains major regulatory phosphoacceptor sites. Indeed, phosphorylation has been demonstrated to modulate the enzymatic activity of topoisomerase II in several species (reviewed in Cardenas and Gasser, 1993) . Recovery of a C-terminal truncation in a screen for drug resistance suggested that this domain either influences the interaction of anti-tumour drugs with topoisomerase II or at least modulates their effect (McPherson et al., 1993) .
Yeast has been demonstrated to be a useful system for the study of topoisomerase 11-mediated drug resistance (Nitiss and Wang, 1988) . However, in all reported cases resistance has been screened under conditions in which the altered form of topoisomerase II also provides the essential DNA topoisomerase II activity for cell division. This automatically restricts the mutants recovered to active forms of the enzyme. With the long-term aim of understanding the mechanism of inhibition and mapping sites of interaction, we have chosen to characterise mutant forms of yeast topoisomerase II in a system in which the ectopic expression of these mutants confers a dominant resistance phenotype against the lethal effects of etoposide . Aliquots were run on SDS -PAGE to determine relative protein concentrations and equal amounts of total protein from each condition were analysed by immunoblotting with affinity-purified antibodies directed against epitopes in the Nterminus of topoisomerase II. The peroxidase-coupled secondary antibody signal was visualised by enhanced chemiluminescence (ECL, Amersham).
Growth curves
Growth curves were measured by dilution of overnight cultures to 5 x 105 cells ml-' in SD-uracil and manual counting of cells at hourly intervals in duplicate. Doubling time was calculated in the most rapid phase of growth, usually between 3 and 12 h after dilution into fresh medium.
Results
The budding yeast, S. cerevisiae, has been used extensively as a test system for mutations that confer resistance to antitumour drugs that target topoisomerase II, but generally in screens for recessive mutations that leave the topoisomerase II active, but drug-resistant (Jannatipour et al., 1993; Wasserman and Wang, 1994a,b; Liu and D'Arpa, 1992; Nitiss et al., 1992 The plasmid-borne TOP2 gene is expressed at a low level under these conditions, but nonetheless renders the cell slightly more sensitive to the inhibitor. This is consistent with previous papers reporting that increased levels of topoisomerase II correlate with the cell's sensitivity to VP-16, VM-26 and other topoisomerase II targeting reagents (Nitiss et al., 1992; Eder et al., 1993; and reviewed in Beck et al., 1993; Corbett and Osheroff, 1993; Liu and D'Arpa, 1992; Alton and Harris, 1993) . In the case of GA81, which is a diploid heterozygotic for the TOP2 locus, we observe somewhat better growth in the presence of VP-16, perhaps reflecting an overall lower level of enzyme. For the sake of standardisation, most experiments will be presented using GA24, although similar results were also obtained with GA81.
Characterisation of topoisomerase II mutants expressed in vivo, and their effect on viability
The above results show that yeast carrying either a vector alone or the vector with the TOP2 gene are sensitive to VP-16 at concentrations between 10 to 30 tg ml-'. In order to analyse the effect of mutant forms of topoisomerase II on drug sensitivity, we checked whether strains expressing the plasmid-borne forms of topoisomerase II were viable in the absence of drugs, whether the truncated forms complement a temperature-sensitive top2 mutation, and, if so, at which levels of expression. The constructs used are C-terminal truncations, of which all but the shortest leave the active site of the enzyme intact and retain the conserved regions homologous to type II topoisomerases, including GyrA and GyrB of E. coli (see Figure 2) . The truncations remove the major sites of casein kinase II modification in the C-terminal 200 aa of the enzyme (indicated as arrows above the gene), and in all but the truncation at aa 1236, nuclear localisation signals (between aa 1166 and 1208, Caron et al., 1994) are removed. All constructs are inserted in the same multicopy vector with a galactose-inducible promoter, which allows differential levels of transcription depending on the carbon source, i.e. glucose allows low levels; raffinose or glycerol/ lactate, intermediate; and galactose, high levels of expression.
Although the GALI UAS is repressed on glucose, sufficient topoisomerase II is synthesised to allow growth in a top2-1 temperature-sensitive mutant at non-permissive temperature (see Table I , 36°C). We similarly screened for the ability of the truncated forms to complement the top2-1 temperaturesensitive mutant at non-permissive temperature (36°C) on different carbon sources. None of the shorter truncations (pGalTop2AI044, A951 or A750) is able to maintain mitotic growth at any level of expression ( Table I ), suggesting that these are inactive forms of the enzyme. The truncation at aa 1236 (A1236) complements better on raffinose than on glucose, suggesting that its level of expression must be elevated to provide sufficient topoisomerase II activity for mitotic growth (Table I) . Galactose-induced expression of either the fulllength TOP2 or the A1236 gene from the multicopy vector is lethal both for wild-type yeast cells (data not shown) and for the top2-1 ts mutant at permissive temperature (see Table I , see galactose, 25°C and 30°C). In contrast, none of the shorter C-terminally truncated forms of topoisomerase II is detrimental to growth at any level of expression (see Table I ).
The inability of the shorter topoisomerase II proteins to inhibit growth when overexpressed, or to complement top2-1 at low levels of expression could simply reflect instability of the message or protein. To (Figure 3c ). For comparison of these protein amounts with endogenous levels of full-length enzyme, a longer exposure of the blot of galactose grown cells is shown (Figure 3d ). In all cases the correct-sized proteins are present, and on galactose all are expressed and stable at levels much greater than the endogenous protein. The truncations are below the level of detection under standard blotting conditions in cells grown on either glycerol/lactate or on glucose media (Figure 3a and b) .
In conclusion, the full-length TOP2 construct and the truncation at A1236 can complement a top2-1Js mutant on the multicopy vector in glucose-containing media, and at this level of expression no construct is detrimental to growth. The truncations at A1044, A951 and A750 cannot complement a top2-1's mutant, although the (Figure 4 ). In the diploid GA81, resistance of the same constructs was observed at 80 jg ml-' VP-16 ( Figure 5 ). Finally, a very similar pattern of slightly elevated resistance was observed when etoposide was replaced by the related topoisomerase II-inhibitor, teniposide (VM-26, data not shown), consistent with the idea that these two agents interact with the enzyme in a similar manner. In all cases the resistance to elevated drug levels is reproducible and construct-dependent.
To mapped the sites of modification to the C-terminal domain Dang et al., 1994; Alghisi et al., 1994 Figure 7 shows the distribution of the mutant and wild-type TOP2 proteins, as detected by indirect immunofluorescence. Because our antibodies cannot distinguish between truncated and wild-type topoisomerase II forms, we always detect low-level immunofluorescence of the endogenous, exclusively nuclear wild-type enzyme (see Figure 7a ; Klein et al., 1992) .
The deletion of the C-terminal 193 aa (A1236) leads to the appearance of significant cytoplasmic staining in addition to strong nuclear staining, while deletion of 385 aa (A1044) leads to a strong cytoplasmic staining with weak nuclear staining (Figure 7c and d) . Cytoplasmic staining is also observed in the shorter truncations A951 and A750, although in these cases the endogenous, wild-type topoisomerase II gives a more prominent signal, because the truncated forms contain fewer epitopes recognised by the polyclonal antibody. As expected, in the strain carrying the pGalTop2Y783F active site mutant, we observe exclusively nuclear staining. The negative control with only secondary antibodies is shown in Figure 7g , confirming that the cytosolic staining in Figure 7b -e is not due to the secondary antibody. Similar results of protein distribution were obtained in crude fractionations of the yeast cell into cytoplasmic and nuclear fractions using sucrose gradients (data not shown).
Ectopic expression of truncated forms of topoisomerase II do not interfere with growth rates The enhanced drug resistance observed in some transformants might be attributed to an altered cell cycle that could either allow degradation of the drug or longer repair times after damage is incurred. To check for alteration in the growth pattern of the transformants, growth curves and doubling times were calculated for the strains carrying truncated forms of topoisomerase II. All have essentially identical growth curves (Figure 8) , 1993; Chan et al., 1993) , and the third approach uses simple and genetically accessible experimental systems like yeast to analyse the phenomenon of drug resistance (Wasserman and Wang, 1994a, b; Nitiss and Wang, 1988; Jannatipour et al., 1993; Liu et al., 1994) . To obtain drug-resistant strains of yeast, several groups have mutagenised the gene for topoisomerase II in vitro and assessed the effect of the mutant gene on drug resistance in a temperature-sensitive yeast strain (Wasserman and Wang, 1994a; Liu et al., 1994 Figure 8) .
A second pattern of drug resistance is mediated by the active site mutation (Y783F (Feldhoff et al., 1994) . In yeast two truncated forms, terminating at aa 1235 and aa 1191, respectively, were shown to confer a low level of drug resistance to amsacrine (at 10 ,g ml-'; Wasserman and Wang, 1994a) . In contrast to our conditions, these mutant forms were selected for their ability to support growth as well as confer drug resistance, hence they were at least partially nuclear and enzymatically active (Wasserman and Wang, 1994a; Caron et al., 1994) . Our screen for dominant drug resistance in yeast can be readily applied to domains of the human topoisomerase Ilx gene, since we are not dependent on complementation of the top2's deficiency.
A final class of mutation that correlates with drug resistance involves the phosphorylation level of topoisomerase II. It is known that phosphorylation of topoisomerase II increases its activity in vitro, while dephosphorylation lowers enzymatic activity (reviewed in Cardenas and Gasser, 1993) . Consistently, an amsacrine-resistant cell line was reported to have a 2-to 3-fold drop in the population of newly synthesised, phosphorylated topoisomerase IIlc (Ganapathi et al., 1993) . On the other hand, a hyperphosphorylated form of topoisomerase II was also reported in an etoposide-resistant human cancer cell line (Takano et al., 1991) (Takano et al., 1991; Ganapathi et al., 1993) . We also observe that elimination of the C-terminal domain, which contains targets for other kinases as well as CKII, improves, rather than reduces, drug resistance in yeast.
The level of drug resistance we observe in yeast is only 2-to 4-fold over the sensitivity of a wild-type strain. This appears modest when compared to the drug resistance in tumour cell lines, which can grow in 20-to 50-fold the amount of drug tolerated by normal cells (reviewed in Beck et al., 1993) . Drug-resistant tumour cells usually incur multiple mutations, however, and the resistance is an accumulative effect of mutations in MDR], topoisomerase IIc and perhaps other unknown targets of mutation. Our degree of enhanced resistance is comparable to the levels observed in transfected HeLa cells, in which small subfragments of human Top20t gene were randomly expressed (Gudkov et al., 1993) . In this HeLa cell study, it was not determined whether the cloned fragment made a stable polypeptide product, nor was the subcellular localisation of the products examined. Indeed, the predicted polypeptide products were small enough to readily diffuse through nuclear pores (< 20 kDa), hence the observed effect might have been due to an allosteric down-regulation of the endogenous topoisomerase II activity. Possible alterations in the growth rates of the drug-resistant cells were not reported.
Our study here has clearly established the fact that a lowlevel expression of inactive forms of DNA topoisomerase II can confer a certain level of drug resistance on otherwise wild-type yeast cells, i.e. cells with a wild-type genomic allele of TOP2. This is clinically relevant, since at early stages in the development of drug resistance, a single mutation in one of the alleles encoding topoisomerase IIo may initially confer a growth advantage on a subset of tumour cells. These cells are then likely to incur further mutations that confer yet higher levels of drug resistance. One immediate application of this assay for a plasmid-mediated drug resistance will be to define protein domains that bind topoisomerase IIinhibiting drugs with high efficiency. Understanding both the mode and site of action for topoisomerase II-targeted drugs will be essential for the improvement of high-dose chemotherapy.
